Metropolis Healthcare Ltd logo

Metropolis Healthcare Ltd

METROPOLIS NSE

Metropolis Healthcare Limited is one of the leading Indian diagnostics companies. The Company owns a chain of diagnostic centres across India, South Asia, Africa and the Middle East.

AI Verdict: HOLD Confidence: 5%

Metropolis Healthcare shows strong TTM profit growth of 40% and favorable analyst sentiment with 78% buy ratings, but the stock trades at an expensive 58.7x PE and 7.41x book value with historically modest sales growth of 11% over 5 years. The risk-reward at current valuations warrants a hold until earnings growth consistency is better established.

Key Fundamentals

MicrocapHealthcare Service ProviderHealthcare Services
Market Cap
₹11,539 Cr
Volatility
Moderate
P/E Ratio
59.25
EBITDA
₹392 Cr
Return on Equity
11.69%
Debt to Equity
0.17
Book Value
₹72.98
EPS
₹26.74
52W High
₹600
52W Low
₹412.25

Technical Indicators

Key Insights

Weaknesses

3
  • Stock is trading at 7.58 times its book value
  • The company has delivered a poor sales growth of 10.5% over past five years.
  • Company has a low return on equity of 12.6% over last 3 years.

Growth Rate

Revenue Growth
22.25% ↗
Net Income Growth
27.48% ↗
Cash Flow Change
-0.50% ↘
ROE
-6.76% ↘
ROCE
-11.55% ↘
EBITDA Margin (Avg.)
-0.80% ↘

AI Analysis — Bull vs Bear

Anthropic anthropic claude-opus-4.6 1d ago
HOLD
Risk high

Metropolis Healthcare shows strong TTM profit growth of 40% and favorable analyst sentiment with 78% buy ratings, but the stock trades at an expensive 58.7x PE and 7.41x book value with historically modest sales growth of 11% over 5 years. The risk-reward at current valuations warrants a hold until earnings growth consistency is better established.

Bull Case 8
  • TTM compounded profit growth of 40% indicates strong near-term earnings acceleration
  • 78% of analysts (14 out of 18) rate the stock a buy, reflecting broad institutional confidence
  • TTM revenue growth of 24% shows meaningful top-line momentum in recent quarters
  • 10-year compounded sales CAGR of 13% demonstrates a durable long-term growth franchise
  • 1-year stock CAGR of 27% reflects positive price momentum and improving market sentiment
  • 10-year ROE of 19% highlights historically strong capital efficiency in the diagnostics business
  • Dividend yield of 0.93% provides some income support, uncommon in high-growth healthcare names
  • Market cap of Rs 11,314 crore positions Metropolis as a mid-large cap with institutional liquidity
Bear Case 8
  • PE ratio of 58.7x is significantly elevated, pricing in years of forward growth with little margin of safety
  • Price-to-book of 7.41x is extremely expensive, flagged as a known concern by screeners
  • 5-year compounded profit CAGR of just 1% shows earnings stagnated over the medium term before recent recovery
  • 5-year stock CAGR of -5% means long-term shareholders have actually lost capital over half a decade
  • 3-year ROE of only 13% (and last year 14%) is below the 10-year average of 19%, suggesting structural dilution of returns
  • 5-year sales growth of only 10.5-11% is modest for a stock commanding a 58.7x multiple
  • Only 11% sell ratings but 11% hold ratings suggest not all analysts are convinced at current levels
  • Low return on equity of 12.6% over 3 years as flagged in known cons indicates capital is not being deployed efficiently relative to valuation premium

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

Anthropic anthropic claude-opus-4.6 14h ago
Neutral 2
  • No new promoter share encumbrance Jun 23

    Metropolis Healthcare promoters confirmed no new encumbrance on shares in FY26. Metz Advisory LLP holds 12 lakh encumbered shares, unchanged.

  • Multiple investor meetings scheduled May 27

    Company scheduled analyst meetings with Macquarie (Jun 8), Morgan Stanley India (Jun 3), and Choice Broking (Jun 11) in 2026, with no unpublished price sensitive information to be shared.

TL;DR: Recent news flow for Metropolis Healthcare is entirely routine and administrative, with no material positive or negative catalysts. Promoter encumbrance remains stable at 12 lakh shares with no new pledges in FY26. Active investor engagement with major brokerages signals continued institutional interest but no directional change. The near-term outlook is neutral pending operational or financial updates.

Quarterly Results

  Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Sales
283
277
308
291
331
313
350
323
345
386
429
406
425
Expenses
212
214
234
226
251
235
260
251
283
296
321
311
317
Operating Profit
70
63
75
65
80
79
90
72
62
90
108
95
108
OPM %
25%
23%
24%
22%
24%
25%
26%
22%
18%
23%
25%
23%
25%
Other Income
1
3
1
2
3
2
3
3
7
8
1
0
8
Interest
6
6
6
5
6
5
5
5
5
5
6
6
8
Depreciation
23
21
22
25
26
26
27
28
29
31
32
32
39
PBT
42
39
48
37
51
51
61
42
36
61
71
57
70
Tax %
20%
26%
26%
26%
28%
25%
24%
26%
19%
26%
26%
26%
27%
Net Profit
33
29
36
27
37
38
47
31
29
45
53
42
51
EPS in Rs
1.63
1.41
1.73
1.33
1.78
1.85
2.27
1.53
1.41
2.17
2.54
2
2.46
Figures in ₹ Crores

Profit & Loss

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Sales
456
475
545
647
761
856
998
1,228
1,148
1,208
1,331
1,646
Expenses
339
359
405
467
559
619
708
880
855
920
1,023
1,245
Operating Profit
117
116
140
181
203
237
290
348
293
288
308
401
OPM %
26%
24%
26%
28%
27%
28%
29%
28%
26%
24%
23%
24%
Other Income
7
29
39
6
8
-17
12
34
15
9
15
17
Interest
2
2
2
4
4
13
12
25
32
28
24
25
Depreciation
21
17
17
19
20
39
46
63
89
94
109
134
PBT
101
128
160
164
187
169
244
293
188
175
191
259
Tax %
33%
36%
33%
32%
34%
24%
25%
27%
24%
26%
24%
26%
Net Profit
68
82
107
112
124
128
183
215
143
128
146
191
EPS in Rs
15.44
20.1
26.61
27.29
5.99
6.29
8.95
10.46
6.98
6.24
7
9.17
Div. Payout %
0%
100%
49%
0%
55%
32%
22%
19%
29%
16%
0%
55%
Figures in ₹ Crores

Balance Sheet

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
10
10
10
10
10
10
10
10
10
10
10
41
Reserves
352
269
314
405
408
513
696
876
978
1,086
1,321
1,472
Borrowings
14
5
1
1
18
67
112
379
266
197
204
232
Other Liabilities
87
107
188
110
113
160
181
256
240
254
324
393
Total Liabilities
462
391
512
526
550
750
1,000
1,521
1,495
1,547
1,859
2,138
Fixed Assets
153
142
202
207
213
296
343
1,059
1,121
1,177
1,447
1,601
CWIP
0
1
1
0
6
3
0
6
20
0
0
0
Investments
168
101
142
102
33
14
10
16
15
55
71
142
Other Assets
141
147
167
216
298
437
647
440
340
316
341
395
Total Assets
462
391
512
526
550
750
1,000
1,521
1,495
1,547
1,859
2,138
Figures in ₹ Crores

Cash Flow

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
69
91
102
104
90
215
249
253
247
264
263
351
Investing
-56
96
-86
1
36
-104
63
-736
48
-89
-199
-223
Financing
-9
-174
-17
-87
-118
-55
-33
163
-292
-181
-87
-115
Net Cash Flow
4
14
-1
18
8
56
279
-321
3
-6
-23
12
Free Cash Flow
46
79
45
90
67
179
221
223
195
200
196
300
CFO/OP
87
113
109
89
78
118
106
96
102
105
99
99
Figures in ₹ Crores

Ratios

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
57
54
54
57
66
55
45
40
39
38
41
38
Inventory Days
52
46
38
53
55
44
59
68
64
58
65
51
Days Payable
92
96
97
88
90
152
160
136
136
150
171
146
Cash Conversion Cycle
17
3
-5
21
30
-54
-56
-29
-33
-53
-65
-57
Working Capital Days
32
8
-27
28
33
2
-9
-26
-22
-16
-18
16
ROCE %
28%
34%
46%
43%
43%
40%
36%
29%
17%
16%
15%
18%

Shareholding Pattern

As of Mar 2026
Promoters 48.87%
DIIs 35.79%
FIIs 10.43%
Public 3.99%
Others 0.92%
Total 100.00%
  Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Promoters
50.38%
50.37%
50.33%
49.50%
49.79%
49.79%
49.76%
49.76%
49.75%
49.75%
49.74%
49.74%
49.67%
49.62%
49.43%
49.40%
48.90%
48.89%
48.89%
48.88%
48.87%
FIIs
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
24.29%
0.00%
18.90%
18.25%
18.56%
16.73%
15.29%
12.83%
12.52%
11.69%
10.43%
DIIs
15.34%
14.22%
11.77%
10.63%
15.32%
13.85%
11.88%
13.30%
13.64%
14.47%
16.86%
20.28%
24.86%
27.43%
28.02%
30.00%
30.30%
32.40%
33.10%
34.73%
35.79%
Government
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
Public
3.95%
3.98%
4.24%
6.50%
9.14%
9.26%
9.45%
9.73%
8.53%
8.15%
7.78%
6.63%
5.24%
4.07%
3.54%
3.34%
3.84%
4.16%
3.69%
3.87%
3.99%
Others
30.33%
31.43%
33.66%
33.37%
25.75%
27.10%
28.91%
27.21%
28.08%
27.62%
1.32%
23.35%
1.33%
0.63%
0.45%
0.53%
1.68%
1.72%
1.80%
0.83%
0.92%
No. of Shareholders
30,679
33,527
43,552
64,168
79,895
86,404
90,090
91,452
84,269
89,692
86,249
79,878
68,283
58,108
51,852
48,572
49,293
50,015
47,846
46,670
48,488

Documents

1
Concall - Jul 2019 Jul 2019
2
Concall - Jul 2019 Jul 2019
3
Concall - Aug 2019 Aug 2019
4
Concall - Aug 2019 Aug 2019
5
Concall - Nov 2019 Nov 2019

Frequently Asked Questions about Metropolis Healthcare Ltd

What does Metropolis Healthcare Ltd do?
Metropolis Healthcare Limited is one of the leading Indian diagnostics companies. The Company owns a chain of diagnostic centres across India, South Asia, Africa and the Middle East.
Where is Metropolis Healthcare Ltd (METROPOLIS) listed?
Metropolis Healthcare Ltd is listed on the Indian stock exchanges. It is listed on NSE: METROPOLIS and BSE: 542650. You can view its live share price, financials, and ratios on Tapetide.
Which sector does Metropolis Healthcare Ltd belong to?
Metropolis Healthcare Ltd operates in the Healthcare sector within the Healthcare Services industry. Sector classification helps investors compare companies affected by similar economic conditions and regulatory changes.
What is the market capitalisation of Metropolis Healthcare Ltd?
Metropolis Healthcare Ltd has a market capitalisation of approximately ₹11538.83 Cr. Based on this, it is classified as a Mid Cap stock.
What is the PE ratio of Metropolis Healthcare Ltd?
The Price-to-Earnings (PE) ratio of Metropolis Healthcare Ltd is 59.25. The PE ratio compares a company's share price to its earnings per share and is commonly used to assess whether a stock is overvalued or undervalued relative to its peers.
What is the 52-week high and low of Metropolis Healthcare Ltd?
Over the past 52 weeks, Metropolis Healthcare Ltd has traded between a low of ₹412.25 and a high of ₹600. This range helps investors understand the stock's price volatility and recent trading levels.
Does Metropolis Healthcare Ltd pay dividends?
Yes, Metropolis Healthcare Ltd has a dividend yield of 0.90%. Dividend yield indicates the annual dividend income relative to the share price. A consistent dividend history can signal financial stability.
What is the Return on Equity (ROE) of Metropolis Healthcare Ltd?
Metropolis Healthcare Ltd has a Return on Equity (ROE) of 11.69%. ROE measures how effectively a company uses shareholders' equity to generate profits. A higher ROE generally indicates better capital efficiency.
How can I research Metropolis Healthcare Ltd on Tapetide?
On Tapetide, you can view Metropolis Healthcare Ltd's live share price, quarterly results, profit & loss statements, balance sheet, cash flow, key ratios, shareholding pattern, technical indicators, analyst ratings, and forecasts — all on a single page without needing to sign up.

Company Information

Metropolis Healthcare Limited is one of the leading Indian diagnostics companies. The Company owns a chain of diagnostic centres across India, South Asia, Africa and the Middle East.

Website metropolisindia.com
CEO Ms. Ameera Sushil Shah
Employees 4,823
Listed 2019-04-15
Face Value ₹ 2
Issued Size 5,18,21,982

Explore More

More in Healthcare → FII DII Data Stock Screener Nifty 50 Heatmap F&O Ban List